Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA)

Site web

Tutelles

Université de Lille
CHU Lille

Texte de présentation

Les axes de recherche développés au sein du Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) sont orientés vers les médicaments injectables, les dispositifs médicaux de perfusion et la modélisation biopharmaceutique et pharmacocinétique. L'unité est une équipe d'accueil (EA 7365) sous la tutelle de l'Université de Lille et du CHU de Lille.

Équipes de recherche

Innovation/évaluation des dispositifs médicaux de perfusion
Innovation/évaluation des médicaments injectables
Modélisation biopharmaceutique et pharmacocinétique

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Site web

Tutelles

Texte de présentation

Équipes de recherche

Dépôts récents

Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trial.

Peri-interventional outcome study in the elderly in Europe A 30-day prospective cohort study

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma

Postoperative lymphopaenia as a risk factor for postoperative infections in cancer surgery: A prospective multicentre cohort study (the EVALYMPH study).

Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial.

Method for the detection and quantification of viral contamination during the preparation of gene therapy drugs in a hospital pharmacy.

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.

Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma.

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Site web

Tutelles

Texte de présentation

Équipes de recherche

Dépôts récents

Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trial. ﻿

Peri-interventional outcome study in the elderly in Europe A 30-day prospective cohort study ﻿

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study. ﻿

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma ﻿

Postoperative lymphopaenia as a risk factor for postoperative infections in cancer surgery: A prospective multicentre cohort study (the EVALYMPH study). ﻿

Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial. ﻿

Method for the detection and quantification of viral contamination during the preparation of gene therapy drugs in a hospital pharmacy. ﻿

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials ﻿

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. ﻿

Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma. ﻿

Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trial.

Peri-interventional outcome study in the elderly in Europe A 30-day prospective cohort study

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma

Postoperative lymphopaenia as a risk factor for postoperative infections in cancer surgery: A prospective multicentre cohort study (the EVALYMPH study).

Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial.

Method for the detection and quantification of viral contamination during the preparation of gene therapy drugs in a hospital pharmacy.

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.

Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma.